Skip to content

Vor Biopharma VOR Payments Of Stock Issuance Costs

Payments Of Stock Issuance Costs at other companies

Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$115.5K
Immunovant, Inc. logo
Immunovant, Inc.IMVT
$126K-60.5%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
Janux Therapeutics logo
Janux TherapeuticsJANX
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN

Other financials

Income statement

See full
Operating income-$35.2M-5.6%
Net income-$219.6M-576%
EPS (diluted)-$5.11+1.9%

Balance sheet

See full
Cash & equivalents$169.9M+239%
Total debt$2.9M-90.5%
Total equity-$150.4M-328%
Total assets$506.7M+364%

Cash flow

See full
Operating cash flow-$38.2M-23.1%
CapEx$48.0K-79.2%
Free cash flow-$38.3M-22.4%

Valuation

See full
Market cap$784.61M+2,594%
Enterprise value$617.68M+5,866%

Returns & leverage

See full
Return on equity-125.4%+671pp
Debt / equity0.5×+0.2×
Current ratio31.1×+27.3×

Where this comes from

Reported directly by Vor Biopharma in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfStockIssuanceCosts.

The official record: Vor Biopharma’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vor Biopharma's payments of stock issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vor Biopharma's payments of stock issuance costs?
Vor Biopharma (VOR) reported payments of stock issuance costs of $127K in Q1 2026.
How has Vor Biopharma's payments of stock issuance costs changed year-over-year?
Vor Biopharma's payments of stock issuance costs decreased by 77.0% year-over-year, from $551K to $127K.